1st December 2017, Volume 130 Number 1466

Richard Beasley, Robert J Hancox

The publication of the Asthma & Respiratory Foundation New Zealand child and adolescent asthma guidelines: a quick reference guide in the New Zealand Medical Journal today1 provides a much needed…

Subscriber content

The full contents of this page is only available to subscribers.

To view this content please login or subscribe

Author Information

Richard Beasley, Medical Research Institute of New Zealand, Wellington, Capital & Coast District Health Board, Wellington; Robert J Hancox, Department of Preventive & Social Medicine, University of Otago, Dunedin.

Correspondence

Professor Richard Beasley, Medical Research Institute of New Zealand, Private Bag 7902, Wellington 6242.

Correspondence Email

richard.beasley@mrinz.ac.nz

Competing Interests

Nil.

References

  1. Asher I, McNamara D, Davies C, et al. Asthma & Respiratory Foundation New Zealand child and adolescent asthma guidelines: a quick reference guide. N Z Med J. 2017; 130(1466):10–33.
  2. Paediatric Society of New Zealand. Best Practice Evidence-Based Guideline: Management of asthma in children aged 1–15 years. 2005. www.paediatrics.org.nz
  3. Beasley R, Hancox R, Harwood M, et al. Asthma and Respiratory Foundation NZ adult asthma guidelines: a quick reference guide. N Z Med J. 2016; 129(1445):83–102.
  4. New Zealand Guidelines Group. Best Practice Evidence-Based Guideline: The diagnosis and treatment of adult asthma. September 2002.
  5. Powell H, Gibson P. High dose versus low dose inhaled corticosteroids as initial starting dose for asthma in adults and children. The Cochrane Collaboration. The Cochrane Library 2008; Issue 4.
  6. Holt S, Suder A, Weatherall M, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ. 2001; 323:253–6.
  7. Masoli M, Weatherall M, Holt S, Beasley R. Systematic review of the dose-response relation of inhaled fluticasone propionate. Arch Dis Child. 2004; 89:902–7.
  8. Kew KM, Karner C, Mindus SM, Ferrara G. Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev 2013:CD009019.
  9. Patel M, Pilcher J, Pritchard A, et al. Efficacy and safety of maintenance and reliever combination budesonide–formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med. 2013; 1:32–42.
  10. Bisgaard H, Le Roux P, Bjamer D, et al. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest. 2006; 130:1733–43.
  11. Edwards SJ, von Maltzahn R, Naya IP, Harrison T. Budesonide/formoterol for maintenance and reliever therapy of asthma: a meta-analysis of randomised controlled trials. Int J Clin Pract. 2010; 64:619–27.
  12. Beasley R, Perrin K, Weatherall M, Wijesinghe M. Call for withdrawal of LABA single-therapy inhaler in asthma. Lancet. 2010; 376:750–1.
  13. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016; 47:410–9.
  14. Agusti A, Bafadhel M, Beasley R, et al. Precision medicine in airway diseases: moving to clinical practice. Eur Respir J. 2017; 50:doi.org/10.1183/13993003.01655-2017.

Download

The downloadable PDF version of this article is only available to subscribers.

To view this content please login or subscribe